Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:GNPX NASDAQ:NMTR NASDAQ:PRQR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeGNPXGenprex$0.58-1.5%$0.86$0.42▼$55.00$6.47M-0.98403,679 shs1.60 million shsNMTR9 Meters Biopharma$0.00$0.07▼$6.56$1.04M1.36315,915 shsN/APRQRProQR Therapeutics$1.89$1.62$1.33▼$3.10$199.13M0.07543,233 shs1.10 million shs(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceGNPXGenprex0.00%-8.93%-28.47%-68.99%-96.14%NMTR9 Meters Biopharma0.00%0.00%0.00%0.00%-99.31%PRQRProQR Therapeutics0.00%+31.25%+31.25%+22.73%-2.58%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeGNPXGenprex$0.58-1.5%$0.86$0.42▼$55.00$6.47M-0.98403,679 shs1.60 million shsNMTR9 Meters Biopharma$0.00$0.07▼$6.56$1.04M1.36315,915 shsN/APRQRProQR Therapeutics$1.89$1.62$1.33▼$3.10$199.13M0.07543,233 shs1.10 million shs(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceGNPXGenprex0.00%-8.93%-28.47%-68.99%-96.14%NMTR9 Meters Biopharma0.00%0.00%0.00%0.00%-99.31%PRQRProQR Therapeutics0.00%+31.25%+31.25%+22.73%-2.58%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceGNPXGenprex 1.00SellN/AN/ANMTR9 Meters Biopharma 0.00N/AN/AN/APRQRProQR Therapeutics 2.63Moderate Buy$7.25283.60% UpsideCurrent Analyst Ratings BreakdownLatest GNPX, PRQR, and NMTR Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/8/2026PRQRProQR Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)5/27/2026PRQRProQR Therapeutics CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingMarket Outperform5/22/2026PRQRProQR Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)4/21/2026GNPXGenprex Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)4/21/2026PRQRProQR Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/9/2026PRQRProQR Therapeutics Chardan CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$4.00(Data available from 6/21/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookGNPXGenprexN/AN/AN/AN/A$2.42 per shareN/ANMTR9 Meters BiopharmaN/AN/AN/AN/A$0.19 per shareN/APRQRProQR Therapeutics$17.99M11.07N/AN/A$0.53 per share3.57Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateGNPXGenprex-$16.23M-$14.14N/AN/AN/AN/A-247.32%-176.73%9/2/2026 (Estimated)NMTR9 Meters Biopharma-$43.77M-$3.46N/AN/AN/AN/A-584.97%-159.45%N/APRQRProQR Therapeutics-$47.73M-$0.50N/AN/AN/A-331.33%-84.87%-37.78%8/6/2026 (Estimated)Latest GNPX, PRQR, and NMTR EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2026Q1 2026GNPXGenprexN/A-$0.64N/A-$0.64N/AN/A5/12/2026Q1 2026PRQRProQR Therapeutics-$0.15-$0.15N/A-$0.15$5.19 million$2.35 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthGNPXGenprexN/AN/AN/AN/AN/ANMTR9 Meters BiopharmaN/AN/AN/AN/AN/APRQRProQR TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioGNPXGenprexN/A5.615.61NMTR9 Meters BiopharmaN/A0.590.59PRQRProQR TherapeuticsN/A2.482.48Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipGNPXGenprex14.05%NMTR9 Meters Biopharma22.34%PRQRProQR Therapeutics32.65%Insider OwnershipCompanyInsider OwnershipGNPXGenprex0.25%NMTR9 Meters Biopharma2.40%PRQRProQR Therapeutics8.40%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableGNPXGenprex2010.93 million10.90 millionNo DataNMTR9 Meters Biopharma2014.34 million13.99 millionNo DataPRQRProQR Therapeutics180105.36 million96.51 millionOptionableGNPX, PRQR, and NMTR HeadlinesRecent News About These CompaniesProQR Therapeutics N.V. (NASDAQ:PRQR) Given Average Recommendation of "Moderate Buy" by BrokeragesJune 15, 2026 | americanbankingnews.comPRQR Share News TodayJune 11, 2026 | uk.investing.comProQR Shareholders Approve Capital Increase, Board Changes at 2026 AGMJune 2, 2026 | tipranks.comProQR Posts Wider Q1 2026 Loss but Maintains Strong Cash PositionMay 17, 2026 | theglobeandmail.comProQR Therapeutics N.V. (NASDAQ:PRQR) Analysts Just Slashed This Year's Revenue Estimates By 22%May 14, 2026 | finance.yahoo.comProQR Announces First Quarter 2026 Operating and Financial ResultsMay 12, 2026 | globenewswire.comProQR Announces Multiple Upcoming Scientific Conference Presentations Highlighting the Breadth of its Axiomer™ RNA Editing PlatformMay 11, 2026 | globenewswire.comEarnings Preview: ProQR (PRQR) Q1 Earnings Expected to DeclineMay 7, 2026 | zacks.comProQR Announces Annual General Meeting of Shareholders to be Held June 2, 2026May 4, 2026 | globenewswire.comProQR Announces Nomination of Dr. Lykke Hinsch Gylvin to its Board of DirectorsApril 30, 2026 | globenewswire.comAnalysts’ Opinions Are Mixed on These Healthcare Stocks: Alkermes (ALKS), ProQR (PRQR) and Simulations Plus (SLP)April 10, 2026 | theglobeandmail.comProQR Therapeutics: Waiting On Proof As AX-0810 Data ApproachesApril 10, 2026 | seekingalpha.comProQR Highlights Pipeline Expansion and Multiple Upcoming Clinical Catalysts at Investor and Analyst EventApril 8, 2026 | globenewswire.comProQR Announces Partnership with Ginkgo Bioworks and Formation of AI Advisory BoardApril 8, 2026 | globenewswire.comGrowing optimism about ProQR Therapeutics (PRQR)’s RNA editing platform and future clinical catalystsMarch 26, 2026 | msn.comGrowing Optimism About ProQR Therapeutics (PRQR)’s RNA Editing Platform and Future Clinical CatalystsMarch 25, 2026 | insidermonkey.comProQR to Host Virtual Investor and Analyst Event Highlighting Pipeline on April 8, 2026March 25, 2026 | globenewswire.comProQR Therapeutics N.V. (PRQR) Presents at The Citizens Life Sciences Conference 2026 TranscriptMarch 18, 2026 | seekingalpha.comProQR (PRQR) Reports Q4 Loss, Lags Revenue EstimatesMarch 12, 2026 | zacks.comProQR Therapeutics N.V.: ProQR Announces Year End 2025 Operating and Financial ResultsMarch 12, 2026 | finanznachrichten.deNew MarketBeat Followers Over TimeMedia Sentiment Over TimeGNPX, PRQR, and NMTR Company DescriptionsGenprex NASDAQ:GNPX$0.58 -0.01 (-1.52%) Closing price 06/18/2026 03:59 PM EasternExtended Trading$0.57 -0.01 (-1.72%) As of 06/18/2026 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Genprex, Inc., a clinical-stage gene therapy company, focuses on developing gene-based therapies for patients with cancer and diabetes in the United States. The company's lead product candidate is REQORSA (GPX-001), which is in preclinical trials to treat non-small cell lung cancer and small cell lung cancer; and GPX-002, which is in preclinical trials to treat type 1 and type 2 diabetes. Its product pipeline comprises Acclaim-1, which is in phase 2a clinical trial for the treatment of non-small cell lung cancer; Acclaim-2, which is in phase phase 1/2 clinical trial for the treatment of non-small cell lung cancer; and Acclaim-3, which is in phase 1/2 clinical trial for the treatment of small cell lung cancer. The company also develops ONC-001, REQORSA as a monotherapy, which is in phase 1 clinical trial to treat advance non-small cell lung cancer; and ONC-002, REQORSA with Tarceva, which is in phase 2 clinical trial to treat non-small cell lung cancer. Genprex, Inc. was incorporated in 2009 and is headquartered in Austin, Texas.9 Meters Biopharma NASDAQ:NMTR9 Meters Biopharma, Inc., a clinical-stage biopharmaceutical company, focuses on treatments for people with rare digestive diseases, gastrointestinal conditions with unmet needs, and debilitating disorders in North America. Its lead product candidate is Vurolenatide, a long-acting injectable glucagon-like-peptide-1 that is in Phase 3 clinical trial to treat short bowel syndrome. The company is developing NM-136, a humanized monoclonal antibody for the treatment of obesity and obesity-related disorders; NM-102, a small molecule peptide to prevent antigens from trafficking into systemic circulation; and NM-003, a proprietary long-acting glucagon-like peptide-2 receptor agonist for prevention of acute graft versus host disease. Its partnered product is Larazotide, an 8-amino acid peptide, which is in Phase 2 clinical trial for treatment of multi-system inflammatory syndrome. The company has licensing agreements with Amunix, MHS Care Innovation LLC, Alba Therapeutics Corporation, and EBRIS. 9 Meters Biopharma, Inc. is headquartered in Raleigh, North Carolina. On July 17, 2023, 9 Meters Biopharma, Inc. filed a voluntary petition for liquidation under Chapter 7 in the U.S. Bankruptcy Court for the Eastern District of North Carolina.ProQR Therapeutics NASDAQ:PRQR$1.89 0.00 (0.00%) Closing price 06/18/2026 04:00 PM EasternExtended Trading$1.86 -0.03 (-1.43%) As of 06/18/2026 07:37 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.ProQR Therapeutics N.V., a biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company's products pipeline includes AX-0810 for cholestatic diseases targeting Na-taurocholate cotransporting polypeptide (NTCP); and AX-1412 for cardiovascular diseases (CVDs) targeting Beta-1,4-galactosyltransferase 1 (B4GALT1). It also develops various other early-stage research programs, including AX-1005 for undisclosed targets in CVDs; AX-2402, which focuses on Rett syndrome; AX-2911 for nonalcoholic steatohepatitis (NASH); AX-0601 for obesity and Type 2 diabetes; and AX-9115 for rare metabolic condition, as well as various other targets. In addition, the company develops Axiomer RNA base-editing platform technology. It has a license agreement with Radboud University Medical Center; Inserm Transfert SA; Ionis Pharmaceuticals, Inc.; Vico Therapeutics B.V.; University of Rochester; and Leiden University Medical Center, as well as license and research collaboration with Eli Lilly and Company for the discovery, development, and commercialization of potential new medicines for genetic disorders in the liver and nervous system. The company was incorporated in 2012 and is headquartered in Leiden, the Netherlands. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 06/15 - 06/19 Satellogic Is Tiny But Its Revenue Growth Is Hard to Ignore Aehr Spikes on New Order, But Has Stock Gotten Ahead of Itself? Why Kroger’s Pullback Could Be a Gift for Patient Investors Credo Technologies Accelerates AI—Its Stock Price Will Follow Why Rocket Lab’s Nasdaq-100 Moment Could Change the Story Why Palantir’s Google Cloud Deal Could Change the Debate VMware: Broadcom's Second Biggest Business Set to Accelerate Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
